Condition

Metastatic Urothelial Carcinoma clinical trials and research

• 20Clinical trials
• 9Countries

Newest Metastatic Urothelial Carcinoma clinical trials

All recruiting trials (20)

• Ivonescimab plus enfortumab vedotin vs pembrolizumab plus enfortumab vedotin in untreated locally advanced or metastatic urothelial cancer

  This trial tests if adding ivonescimab to enfortumab vedotin works better than pembrolizumab plus enfortumab vedotin for people with untreated locally advanced or metastatic urothelial cancer.

  Recruiting at 2 sites Phase 2/3 Summit Therapeutics · Phoenix, Arizona and 6 other locations · NCT07815665

• Imaging Test for Metastatic Urothelial and Breast C cancers and NSCLC

  This imaging study tests how well the imaging agent works in people with metastatic urothelial cancer, various breast cancers, or NSCLC.

  Recruiting at 4 sites Early Phase 1 RayzeBio, Inc. · St Leonards, New South Wales and 5 other locations · NCT07671092

• Dual-target Nectin-4 and HER2 CAR-NK therapy for advanced urothelial carcinoma

  This treatment will try dual-target CAR-NK cells that recognize Nectin‑4 and HER2 in adults with relapsed or metastatic urothelial carcinoma after standard therapies.

  Recruiting Phase 1 Beijing Biotech · Shenzhen, Guangdong · NCT07492628

• GB-4362 combined with enfortumab vedotin and pembrolizumab for advanced urothelial cancer

  This study will test adding GB-4362 to enfortumab vedotin and pembrolizumab to see if it lowers treatment-related side effects like nerve damage in adults with advanced or metastatic urothelial cancer.

  Recruiting at 10 sites Phase 1 Generate Biomedicines · Duarte, California and 9 other locations · NCT07484022

• Nerve effects of enfortumab vedotin in people with urothelial cancer

  We will see how nerve testing and patient-reported symptoms change in adults with urothelial cancer who are starting enfortumab vedotin.

  Recruiting at 7 sites Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07390617

• Choosing first-line treatment for metastatic urothelial carcinoma

  This study will look at adults with metastatic urothelial carcinoma treated since October 2024 to see which patient features and clinician reasons lead to choosing platinum-based chemotherapy instead of enfortumab vedotin plus pembrolizumab as first-line therapy.

  Recruiting University Hospital, Strasbourg, France · Strasbourg · NCT07339878

• Pembrolizumab maintenance after initial enfortumab vedotin plus pembrolizumab for frontline metastatic urothelial cancer

  This trial will test whether continuing pembrolizumab after an 18-week course of enfortumab vedotin plus pembrolizumab helps people with previously untreated metastatic urothelial carcinoma.

  Recruiting Phase 2 Fox Chase Cancer Center · Philadelphia, Pennsylvania · NCT07221942

• Enfortumab vedotin for advanced urothelial (bladder) cancer in Indian adults

  This trial will test enfortumab vedotin given by IV infusion in Indian adults whose urothelial cancer has spread and progressed after prior treatments.

  Recruiting at 15 sites Phase 4 Astellas Pharma Inc · Patna, Bihar and 14 other locations · NCT06862219

• Pembrolizumab plus sacituzumab govitecan versus standard treatments for advanced urothelial cancer

  This trial will test whether adding sacituzumab govitecan to pembrolizumab works better than standard chemotherapy options for adults with locally advanced or metastatic urothelial cancer who have progressed after prior therapy.

  Recruiting at 161 sites Phase 3 National Cancer Institute (NCI) · Phoenix, Arizona and 162 other locations · NCT06524544

• Treatment for solid tumors with high EphrinB2 expression using sEphB4-HSA

  This study is testing a new treatment combining sEphB4-HSA with pembrolizumab to see if it helps people with advanced bladder cancer that has high levels of EphrinB2 feel better compared to standard chemotherapy.

  Recruiting Phase 2/3 Vasgene Therapeutics, Inc · Santa Monica, California · NCT06493552

• Combining pembrolizumab and CA-4948 for advanced urothelial cancer treatment

  This study is testing a new combination of two drugs, pembrolizumab and CA-4948, to see if it can help people with advanced urothelial cancer that hasn't responded to other treatments.

  Recruiting at 11 sites Phase 1 National Cancer Institute (NCI) · Duarte, California and 10 other locations · NCT06439836

• Comparing home and clinic administration of nivolumab for cancer treatment

  This study tests whether giving cancer patients their treatment at home instead of in a clinic makes them feel better and prefer their care more.

  Recruiting Phase 2 Mayo Clinic · Jacksonville, Florida · NCT06265285

• CPI-613 combined with hydroxychloroquine and chemotherapy for advanced solid tumors

  This study is testing a new combination of treatments, including CPI-613 and hydroxychloroquine, to see if it can help people with advanced solid tumors that haven't improved with other chemotherapy.

  Recruiting Phase 2 Northwestern University · Chicago, Illinois · NCT05733000

• Personalized vaccine combined with pembrolizumab for advanced solid tumors

  This study is testing a new personalized cancer vaccine combined with pembrolizumab to see if it helps people with advanced solid tumors fight their cancer better.

  Recruiting Phase 1/2 Mayo Clinic · Jacksonville, Florida · NCT05269381

• Evaluating NX-1607 for advanced cancers

  This study is testing a new treatment called NX-1607 to see if it can help people with advanced cancers who have run out of other options.

  Recruiting at 15 sites Phase 1 Nurix Therapeutics, Inc. · Duarte, California and 16 other locations · NCT05107674

• Combining cabozantinib and enfortumab vedotin for advanced bladder cancer

  This study is testing a new combination of two drugs, cabozantinib and enfortumab vedotin, to see if it can help people with advanced bladder cancer feel better and live longer.

  Recruiting Phase 1 Emory University · Atlanta, Georgia · NCT04878029

• Sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial cancer

  This trial tests whether combining sacituzumab govitecan and enfortumab vedotin, with pembrolizumab in some patients, helps people with metastatic urothelial carcinoma who have progressed after platinum chemotherapy and PD‑1/PD‑L1 inhibitors.

  Recruiting Phase 1/2 Dana-Farber Cancer Institute · Boston, Massachusetts · NCT04724018

• Combining cryoablation and radiation therapy for painful bone metastases

  This study is testing if combining a freezing treatment with radiation can help people with painful bone cancer feel better compared to just using radiation alone.

  Recruiting M.D. Anderson Cancer Center · Houston, Texas · NCT04693377

• Identifying urine markers to predict responses to immunotherapy in bladder cancer patients

  This study is testing if certain markers in urine can help predict how well immunotherapy will work for people with advanced bladder cancer.

  Recruiting National Taiwan University Hospital · Taipei · NCT04641936

• Understanding how kidney tumors use nutrients for growth

  This study tests how kidney tumors use certain nutrients to grow by giving participants a special nutrient infusion during surgery and checking their blood and tissue samples.

  Recruiting University of Texas Southwestern Medical Center · Dallas, Texas · NCT04623502

Related topics

Quick answers

How many Metastatic Urothelial Carcinoma clinical trials are recruiting right now?

20, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 9 countries. The most sites are in United States (15 trials), Taiwan (1 trial), India (1 trial), China (1 trial), United Kingdom (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1: 5, Phase 2: 3, Phase 2/3: 2, Phase 1/2: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →